A number of prominent proteomics-based diagnostics developers were recipients of the grant and tax credit awards, which are being provided by the IRS through the Patient Protection and Affordable Care Act's Qualifying Therapeutic Discovery Project Program.
NCI has outlined changes to its IP policies for collaborative research agreements that would essentially provide industry collaborators with first-option commercial licensing rights for IP arising from studies that make use of pharma companies' proprietary drugs, or samples from patients treated with those drugs.
In addition to several PGx studies presented at the conference, the International Association for the Study of Lung Cancer and the European Thoracic Oncology Platform's European EGFR Workshop Group proposed recommendations on EGFR mutation testing in NSCLC when patients are treated with AstraZeneca's Iressa.
At the European Lung Cancer Conference last week in Geneva, Biodesix presented data from a multi-center Phase III study that showed VeriStrat was able to identify NSCLC patients most likely to have a "significant survival benefit" from treatment with Tarceva.
The results, presented today at the Second European Lung Cancer Conference, indicate that the MALDI-based test could differentiate which patients would benefit from erlotinib treatment and which wouldn't.